Moderna Launched The Clinical Trial of Its First Quadrivalent Seasonal Influenza mRNA Vaccine And Completed The First Ba

1. Huateng Pharma https://en.huatengsci.com Moderna Launched The Clinical Trial of Its First Quadrivalent Seasonal Influenza mRNA Vaccine And Completed The First Batch of Vaccinations On July 7, Moderna announced the first participants have been dosed in the Phase 1/2 study of mRNA-1010. Its research vaccine mRNA-1010 is a quadrivalent seasonal influenza vaccine candidate targeting WHO recommendations including A H1N1, H3N2 and influenza B Yamagata and Victoria lineages. The press release states that it is Moderna's first seasonal flu vaccine candidate product that has entered clinical development. 3-D print of influenza virus. The Phase 1/2 clinical trial aims to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1010 in healthy adults 18 years and older. There are about 180 subjects will enroll in the trial. The epidemic of seasonal influenza causes respiratory diseases and places a

2. Huateng Pharma huge burden on the healthcare system. According to WHO estimates, there are about 3 million to 5 million severe cases of influenza worldwide each year, and about 290,000 to 650,000 deaths from influenza-related respiratory diseases occur. https://en.huatengsci.com However, the current flu vaccines are only approximately 40-60% effective and their formulation is decided 6-9 months before the vaccines are intended to be used. Moreover, most of the licensed influenza vaccines use egg-based vaccine production which may cause unintended antigenic change to the vaccine virus. Potential advantages of an mRNA vaccine "Seasonal influenza vaccine candidate products will become an important part of our future respiratory vaccines." Mr. Stéphane Bancel, CEO of Moderna, said, "Respiratory vaccines are one of the important pillars of our mRNA vaccine strategy. We believe that the advantages of an mRNA vaccine include the ability to combine different antigens, prevent multiple viruses, and have the ability to rapidly respond to the evolution of respiratory viruses, such as influenza viruses, novel coronavirus, and respiratory syncytial viruses. Our vision is to develop an mRNA combination vaccine that allows people to be vaccinated once in each fall to provide effective protection against the most threatening respiratory viruses." As a dynamic science company, Huateng Pharma is dedicated to providing PEG derivatives and pharmaceutical intermediates to customers all over the world. We can supply kinds of excipients used in COVID-19 vaccines, such as mPEG-DTA

3. Huateng Pharma (ALC-0159), mPEG-DMG, mPEG-DSPE, mPEG-CH2CH2CH2-NH2 and so on. We can also supply many kinds of intermediates for anti-viral drugs, such as oseltamivir intermediates, remdesivir intermediates, Entecavir Intermediates​ , Brilacidin intermediates, baloxavir marboxil intermediates, Peramivir intermediates etc. https://en.huatengsci.com Reference: [1] Moderna Announces First Participant Dosed in Phase 1/2 Study of Its Quadrivalent Seasonal Flu mRNA Vaccine. Retrieved July 7, 2021 [2] Moderna begins human trial for multi-strain mRNA flu vaccine